例如:"lncRNA", "apoptosis", "WRKY"

Blood and brain protein levels of ubiquitin-conjugating enzyme E2K (UBE2K) are elevated in individuals with schizophrenia.

J Psychiatr Res. 2019 Jun;113:51-57. Epub 2019 Mar 08
Hannah Meiklejohn 1 , Md Shaki Mostaid 2 , Sandra Luza 3 , Serafino G Mancuso 4 , Dali Kang 4 , Sonny Atherton 3 , Debora A Rothmond 5 , Cynthia Shannon Weickert 6 , Carlos M Opazo 3 , Christos Pantelis 7 , Ashley I Bush 8 , Ian P Everall 9 , Chad A Bousman 10
Hannah Meiklejohn 1 , Md Shaki Mostaid 2 , Sandra Luza 3 , Serafino G Mancuso 4 , Dali Kang 4 , Sonny Atherton 3 , Debora A Rothmond 5 , Cynthia Shannon Weickert 6 , Carlos M Opazo 3 , Christos Pantelis 7 , Ashley I Bush 8 , Ian P Everall 9 , Chad A Bousman 10
+ et al

[No authors listed]

Author information
  • 1 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC, Australia; Melbourne Medical School, Faculty of Medicine Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia.
  • 2 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia; Departments of Medical Genetics, Psychiatry, and Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • 3 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC, Australia; Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.
  • 4 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC, Australia.
  • 5 Schizophrenia Research Laboratory, Neuroscience Research Australia, Barker Street, Sydney, Australia; School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia.
  • 6 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC, Australia; Schizophrenia Research Laboratory, Neuroscience Research Australia, Barker Street, Sydney, Australia; School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia; Department of Neuroscience & Physiology, Upstate Medical University, Syracuse, New York 13210, USA.
  • 7 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia; Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia; Centre for Neural Engineering, Department of Electrical and Electronic Engineering, The University of Melbourne, Carlton, VIC, Australia; NorthWestern Mental Health, Melbourne, Victoria, Australia.
  • 8 The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia; Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.
  • 9 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia; Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia; Centre for Neural Engineering, Department of Electrical and Electronic Engineering, The University of Melbourne, Carlton, VIC, Australia; Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.
  • 10 Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC, Australia; The Cooperative Research Centre (CRC) for Mental Health, Victoria, Australia; Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada; Departments of Medical Genetics, Psychiatry, and Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: chad.bousman@ucalgary.ca.

摘要


A number of recent studies have suggested the ubiquitin proteasome system (UPS) in schizophrenia is dysfunctional. The purpose of this study was to investigate UBE2K, a ubiquitin-conjugating (E2) enzyme within the UPS that has been associated with psychosis symptom severity, in the blood and brain of individuals with schizophrenia. Whole blood and erythrocytes from 128 (71 treatment-resistant schizophrenia, 57 healthy controls) individuals as well as frozen dorsolateral prefrontal cortex (DLPFC) and orbitofrontal cortex (OFC) post-mortem samples from 74 (37 schizophrenia, 37 controls) individuals were obtained. UBE2K gene expression was assayed in whole blood and DLPFC samples, whereas protein levels were assayed in erythrocytes and OFC samples. Elevated levels of UBE2K mRNA were observed in whole blood of individuals with schizophrenia (p = 0.03) but not in the DLPFC, while protein levels were raised in erythrocytes and the OFC (p < 0.001 and p = 0.002 respectively). Findings were not better explained by age, smoking, clozapine plasma levels or duration of illness. Although blood and brain samples were derived from independent samples, our findings suggest peripheral protein levels of UBE2K may serve as a surrogate of brain levels and further supports the notion of UPS dysfunction in schizophrenia. Future studies to determine the pathophysiological effects of elevated UBE2K protein levels in the brain of those with schizophrenia are warranted.

KEYWORDS: Gene expression, Post-mortem, Protein expression, Schizophrenia, Treatment-resistant, UBE2K, Ubiquitin